Profile
Michael D.
Wyzga served as Vice President-Healthcare Investment at Needham & Co. LLC from 2018 to 2021.
Prior to that, he was the Chief Financial Officer and Senior VP at Yumanity Therapeutics, Inc. and Kineta, Inc. respectively.
He completed his undergraduate degree at Lehigh University and earned an MBA from SC Johnson College of Business.
Former positions of Michael Wyzga
Companies | Position | End |
---|---|---|
Needham & Co. LLC
Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Corporate Officer/Principal | 2021-07-31 |
KINETA, INC. | Director of Finance/CFO | - |
YUMANITY THERAPEUTICS | Director of Finance/CFO | - |
Training of Michael Wyzga
Lehigh University | Undergraduate Degree |
SC Johnson College of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
KINETA, INC. | Health Technology |
Private companies | 2 |
---|---|
Needham & Co. LLC
Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Finance |
Yumanity Therapeutics, Inc.
Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Michael Wyzga